Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy

Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales

(2021) James K. Carter et al.   PLoS One

Hepatocellular carcinoma

(2021) Josep M. Llovet et al.   Nature Reviews Disease Primers

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

(2021) Dominik Pfister et al.   NATURE

Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH

(2021) Michael Dudek et al.   NATURE

Motility Dynamics of T Cells in Tumor-Draining Lymph Nodes: A Rational Indicator of Antitumor Response and Immune Checkpoint Blockade

(2021) Yasuhiro Kanda et al.   Cancers

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

(2020) Bruno Sangro et al.   JOURNAL OF HEPATOLOGY

Steatohepatitis Impairs T cell-directed Immunotherapies Against Liver Tumors in Mice

(2020) Bernd Heinrich et al.   GASTROENTEROLOGY

Metformin enhances anti-mycobacterial responses by educating CD8+ T-cell immunometabolic circuits

(2020) Julia Böhme et al.   Nature Communications

Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease

(2018) Francesca Romana Ponziani et al.   HEPATOLOGY

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

(2018) Christopher S. Garris et al.   IMMUNITY

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade

(2018) Ziming Wang et al.   NATURE MEDICINE

NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis

(2016) Chi Ma et al.   NATURE